Aspiration Therapy As a Tool to Treat Obesity: 1- to 4-Year Results in a 201-Patient Multi-Center Post-Market European Registry Study
| Autor: | Roman Turro Arau, Jesus Turró Homedes, Max Nyström, Erik Norén, Pier Alberto Testoni, Evzen Machytka, Jorge Carlos Espinos Perez, Ignace M. C. Janssen |
|---|---|
| Přispěvatelé: | Nyström, Max, Machytka, Evzen, Norén, Erik, Testoni, Pier Alberto, Janssen, Ignace, Turró Homedes, Jesu, Espinos Perez, Jorge Carlo, Turro Arau, Roman |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Bariatrics Original Contributions Endocrinology Diabetes and Metabolism medicine.medical_treatment Blood Pressure 030209 endocrinology & metabolism Suction Body Mass Index Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Weight loss Diabetes mellitus Internal medicine Percutaneous endoscopic gastrostomy Weight Loss Diabetes Mellitus medicine Humans Obesity Registries Life Style Aged Gastrostomy Glycated Hemoglobin Nutrition and Dietetics business.industry Middle Aged medicine.disease Obesity Morbid Europe Aspiration therapy endoscopic weight loss Blood pressure chemistry Female 030211 gastroenterology & hepatology Surgery Glycated hemoglobin medicine.symptom business Body mass index |
| Zdroj: | Obesity Surgery |
| ISSN: | 1708-0428 0960-8923 |
| DOI: | 10.1007/s11695-017-3096-5 |
| Popis: | Purpose The objective of this post-market study was to evaluate long-term safety and efficacy of aspiration therapy (AT) in a clinical setting in five European clinics. Materials and Methods The AspireAssist® System (Aspire Bariatrics, Inc. King of Prussia, PA) is an endoscopic weight loss therapy utilizing a customized percutaneous endoscopic gastrostomy tube and an external device to aspirate approximately 30% of ingested calories after a meal, in conjunction with lifestyle counseling. A total of 201 participants, with body mass index (BMI) of 35.0–70.0 kg/m2, were enrolled in this study from June 2012 to December 2016. Mean baseline BMI was 43.6 ± 7.2 kg/m2. Results Mean percent total weight loss at 1, 2, 3, and 4 years, respectively, was 18.2% ± 9.4% (n/N = 155/173), 19.8% ± 11.3% (n/N = 82/114), 21.3% ± 9.6% (n/N = 24/43), and 19.2% ± 13.1% (n/N = 12/30), where n is the number of measured participants and N is the number of participants in the absence of withdrawals or lost to follow-up. Clinically significant reductions in glycated hemoglobin (HbA1C), triglycerides, and blood pressure were observed. For participants with diabetes, HbA1C decreased by 1% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink